Fulcrum Therapeutics, Inc.FULCNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank38
3Y CAGR-9.9%
5Y CAGR-1.0%
Year-over-Year Change
Research and development spending
3Y CAGR
-9.9%/yr
vs +32.1%/yr prior
5Y CAGR
-1.0%/yr
Recent deceleration
Acceleration
-42.1pp
Decelerating
Percentile
P38
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
3 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $56.10M | -11.5% |
| 2024 | $63.39M | -11.7% |
| 2023 | $71.80M | -6.5% |
| 2022 | $76.78M | +10.2% |
| 2021 | $69.70M | +18.1% |
| 2020 | $59.04M | +36.0% |
| 2019 | $43.43M | +72.4% |
| 2018 | $25.18M | +36.2% |
| 2017 | $18.49M | - |